Europeiska unionen - svenska - EMA (European Medicines Agency)

viatris limited - pirfenidon - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunsuppressiva - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 10 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 10,844 mg aktiv substans - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 20 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 21,688 mg aktiv substans - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 40 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 43,376 mg aktiv substans - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 80 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 86,751 mg aktiv substans - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

vianex s.a. - oxaliplatin - pulver till infusionsvätska, lösning - 5 mg/ml - laktosmonohydrat hjälpämne; oxaliplatin 5 mg aktiv substans - oxaliplatin

Europeiska unionen - svenska - EMA (European Medicines Agency)

viatris limited - klopidogrelbesilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiska medel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentet höjd akut hjärtinfarkt, i kombination med asa i medicinskt behandlade patienter berättigade till trombolysbehandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. för ytterligare information hänvisas till avsnitt 5.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - atenolol - tablett - 25 mg - atenolol 25 mg aktiv substans - atenolol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - atenolol - tablett - 50 mg - atenolol 50 mg aktiv substans - atenolol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

viatris limited - apixaban - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; apixaban 5 mg aktiv substans; laktos (vattenfri) hjälpämne